重新定义临床无意义前列腺癌:根治性前列腺切除术后生化复发风险分析
该研究纳入1998年9月至2019年3月在西澳大利亚接受根治性前列腺切除术的3784例前列腺局限且切缘阴性、Gleason评分≤6或3+4的患者,中位随访96.8个月,生化复发110例(2.91%)。研究未支持Stamey或Epstein基于肿瘤体积<0.5 mL、Gleason评分<7及局限切缘阴性疾病的无意义癌标准,所有组均存在生化复发风险,建议将无意义癌重新定义为「低风险」癌并扩大其范围至含少量Gleason 4成分的较小肿瘤。
要点
- 肿瘤体积<0.5 mL与0.5-2.0 mL在Gleason 6或3+4患者中生化复发率无统计学差异。
- Gleason 4成分≤20%时,肿瘤体积≤2 mL与>2 mL的生化复发率无统计学差异。
- Gleason 4成分增至30%时,>2 mL肿瘤的生化复发显著增加。
核心结论
- 研究未支持Stamey或Epstein基于肿瘤体积<0.5 mL、Gleason评分<7及局限切缘阴性疾病的无意义癌标准。
- 未发现无风险的癌,所有组均存在一定生化复发风险,应将无意义癌重新定义为「低风险」癌并扩大范围至含少量Gleason 4成分的较小肿瘤。
研究设计与样本
- 回顾性队列研究,纳入1998年9月至2019年3月在西澳大利亚接受根治性前列腺切除术的3784例患者。
- 纳入患者Gleason评分≤6或3+4、前列腺局限且切缘阴性,采用逻辑回归模型分析病理数据。
主要发现
- 中位随访96.8个月,110例(2.91%)发生生化复发。
- 肿瘤体积<0.5 mL与0.5-2.0 mL在Gleason 6或3+4患者中的失败率无统计学差异。
- Gleason 4成分≤20%时,肿瘤体积≤2 mL与>2 mL的失败率无统计学差异;Gleason 4成分增至30%时,>2 mL肿瘤的生化复发显著增加。
关键数值与推荐
- 生化复发定义为术后随访期间出现,共110例(2.91%)。
- 肿瘤体积分组界值为0.5 mL和2.0 mL。
- Gleason 4成分百分比界值为20%和30%。
临床怎么用
- 临床咨询中不应将满足Stamey或Epstein标准的肿瘤视为无复发风险,应告知患者仍存在生化复发可能。
- 对于含少量Gleason 4成分(≤20%)且肿瘤体积≤2 mL的较小肿瘤,可考虑归入「低风险」范畴而非「无意义」癌。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the risk of biochemical recurrence (BCR) in small low-grade prostate tumors following radical prostatectomy (RP), which are defined as clinically insignificant based on the existing criteria developed by Stamey and Epstein. MATERIALS AND METHODS: We identified 3784 men who underwent RP in Western Australia from September 1998 to March 2019. These patients had a Gleason sum (GS) of ≤6 or 3+4, prostate confined and negative margins. Pathological data analysis was performed using logistic regression modeling. RESULTS: Median follow-up was 96.8 months. BCR occurred in 110 men (2.91%). There was no statistical difference in the rates of failure for patients with a tumor volume <0.5 mL vs 0.5-2.0 mL when comparing (i) those with Gleason 6, or (ii) those with Gleason 3+4. Furthermore, there was no statistical difference in rates of failure when comparing patients with a tumor volume of ≤2 mL vs >2 mL when the percentage of Gleason pattern 4 was ≤20%. However, once the percentage of Gleason pattern 4 increased to 30%, there was a significant increase in BCR in the larger tumors (> 2 mL). CONCLUSION: This study did not support either Stamey's or Epstein's criteria of insignificant cancer based on volumes of less than 0.5 mL, GS <7 and confined margin negative disease. No risk free cancer was identified, as all groups demonstrated some risk of BCR. This study redefines the entity of insignificant cancer as rather "low risk" cancer and expands its scope to include smaller tumors with minor Gleason pattern 4 components.
引用
- Frankcombe DE, Li J, Cohen RJ, et al. Redefining the Concept of Clinically Insignificant Prostate Cancer. Urology. 2019. PMID: 31715271. doi:10.1016/j.urology.2019.10.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。